Akt/cAMP-responsive element binding protein/cyclin D1 network: A novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a Phellodendron amurense bark extract

Addanki P Kumar, Shylesh Bhaskaran, Manonmani Ganapathy, Katherine Crosby, Michael D. Davis, Peter Kochunov, John Schoolfield, I. Tien Yeh, Dean A. Troyer, Rita Ghosh

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Purpose: Development of prostate cancer prevention strategies is an important priority to overcome high incidence, morbidity, and mortality. Recently, we showed that Nexrutine, an herbal extract, inhibits prostate cancer cell proliferation through modulation of Akt and cAMP-responsive element binding protein (CREB) - mediated signaling pathways. However, it is unknown if Nexrutine can be developed as a dietary supplement for the prevention of prostate cancer. In this study, we used the transgenic adenocarcinoma of mouse prostate (TRAMP) model to examine the ability of Nexrutine to protect TRAMP mice from developing prostate cancer. Experimental Design: Eight-week-old TRAMP mice were fed with pelleted diet containing 300 and 600 mg/kg Nexrutine for 20 weeks. Efficacy of Nexrutine was evaluated by magnetic resonance imaging at 18 and 28 weeks of progression and histologic analysis of prostate tumor or tissue at the termination of the experiment. Tumor tissue was analyzed for modulation of various signaling molecules. Results: We show that Nexrutine significantly suppressed palpable tumors and progression of cancer in the TRAMP model. Expression of total and phosphorylated Akt, CREB, and cyclin D1 was significantly reduced in prostate tissue from Nexrutine intervention group compared with tumors from control animals. Nexrutine also inhibited cyclin D1 transcriptional activity in androgen-independent PC-3 cells. Overexpression of kinase dead Akt mutant or phosphorylation-defective CREB inhibited cyclin D1 transcriptional activity. Conclusions: The current study shows that Nexrutine-mediated targeting of Akt/CREB - induced activation of cyclin D1 prevents the progression of prostate cancer. Expression of CREB and phosphorylated CREB increased in human prostate tumors compared with normal tissue, suggesting their potential use as prognostic markers.

Original languageEnglish (US)
Pages (from-to)2784-2794
Number of pages11
JournalClinical Cancer Research
Volume13
Issue number9
DOIs
StatePublished - May 1 2007

Fingerprint

Phellodendron
Cyclin D1
Transgenic Mice
Prostate
Prostatic Neoplasms
Carrier Proteins
Adenocarcinoma
Neoplasms
Nexrutine
Dietary Supplements
Androgens
Research Design
Phosphotransferases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Akt/cAMP-responsive element binding protein/cyclin D1 network : A novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a Phellodendron amurense bark extract. / Kumar, Addanki P; Bhaskaran, Shylesh; Ganapathy, Manonmani; Crosby, Katherine; Davis, Michael D.; Kochunov, Peter; Schoolfield, John; Yeh, I. Tien; Troyer, Dean A.; Ghosh, Rita.

In: Clinical Cancer Research, Vol. 13, No. 9, 01.05.2007, p. 2784-2794.

Research output: Contribution to journalArticle

Kumar, Addanki P ; Bhaskaran, Shylesh ; Ganapathy, Manonmani ; Crosby, Katherine ; Davis, Michael D. ; Kochunov, Peter ; Schoolfield, John ; Yeh, I. Tien ; Troyer, Dean A. ; Ghosh, Rita. / Akt/cAMP-responsive element binding protein/cyclin D1 network : A novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a Phellodendron amurense bark extract. In: Clinical Cancer Research. 2007 ; Vol. 13, No. 9. pp. 2784-2794.
@article{71d7282c046a4c94b37b319ce06c20d1,
title = "Akt/cAMP-responsive element binding protein/cyclin D1 network: A novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a Phellodendron amurense bark extract",
abstract = "Purpose: Development of prostate cancer prevention strategies is an important priority to overcome high incidence, morbidity, and mortality. Recently, we showed that Nexrutine, an herbal extract, inhibits prostate cancer cell proliferation through modulation of Akt and cAMP-responsive element binding protein (CREB) - mediated signaling pathways. However, it is unknown if Nexrutine can be developed as a dietary supplement for the prevention of prostate cancer. In this study, we used the transgenic adenocarcinoma of mouse prostate (TRAMP) model to examine the ability of Nexrutine to protect TRAMP mice from developing prostate cancer. Experimental Design: Eight-week-old TRAMP mice were fed with pelleted diet containing 300 and 600 mg/kg Nexrutine for 20 weeks. Efficacy of Nexrutine was evaluated by magnetic resonance imaging at 18 and 28 weeks of progression and histologic analysis of prostate tumor or tissue at the termination of the experiment. Tumor tissue was analyzed for modulation of various signaling molecules. Results: We show that Nexrutine significantly suppressed palpable tumors and progression of cancer in the TRAMP model. Expression of total and phosphorylated Akt, CREB, and cyclin D1 was significantly reduced in prostate tissue from Nexrutine intervention group compared with tumors from control animals. Nexrutine also inhibited cyclin D1 transcriptional activity in androgen-independent PC-3 cells. Overexpression of kinase dead Akt mutant or phosphorylation-defective CREB inhibited cyclin D1 transcriptional activity. Conclusions: The current study shows that Nexrutine-mediated targeting of Akt/CREB - induced activation of cyclin D1 prevents the progression of prostate cancer. Expression of CREB and phosphorylated CREB increased in human prostate tumors compared with normal tissue, suggesting their potential use as prognostic markers.",
author = "Kumar, {Addanki P} and Shylesh Bhaskaran and Manonmani Ganapathy and Katherine Crosby and Davis, {Michael D.} and Peter Kochunov and John Schoolfield and Yeh, {I. Tien} and Troyer, {Dean A.} and Rita Ghosh",
year = "2007",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-06-2974",
language = "English (US)",
volume = "13",
pages = "2784--2794",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Akt/cAMP-responsive element binding protein/cyclin D1 network

T2 - A novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a Phellodendron amurense bark extract

AU - Kumar, Addanki P

AU - Bhaskaran, Shylesh

AU - Ganapathy, Manonmani

AU - Crosby, Katherine

AU - Davis, Michael D.

AU - Kochunov, Peter

AU - Schoolfield, John

AU - Yeh, I. Tien

AU - Troyer, Dean A.

AU - Ghosh, Rita

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Purpose: Development of prostate cancer prevention strategies is an important priority to overcome high incidence, morbidity, and mortality. Recently, we showed that Nexrutine, an herbal extract, inhibits prostate cancer cell proliferation through modulation of Akt and cAMP-responsive element binding protein (CREB) - mediated signaling pathways. However, it is unknown if Nexrutine can be developed as a dietary supplement for the prevention of prostate cancer. In this study, we used the transgenic adenocarcinoma of mouse prostate (TRAMP) model to examine the ability of Nexrutine to protect TRAMP mice from developing prostate cancer. Experimental Design: Eight-week-old TRAMP mice were fed with pelleted diet containing 300 and 600 mg/kg Nexrutine for 20 weeks. Efficacy of Nexrutine was evaluated by magnetic resonance imaging at 18 and 28 weeks of progression and histologic analysis of prostate tumor or tissue at the termination of the experiment. Tumor tissue was analyzed for modulation of various signaling molecules. Results: We show that Nexrutine significantly suppressed palpable tumors and progression of cancer in the TRAMP model. Expression of total and phosphorylated Akt, CREB, and cyclin D1 was significantly reduced in prostate tissue from Nexrutine intervention group compared with tumors from control animals. Nexrutine also inhibited cyclin D1 transcriptional activity in androgen-independent PC-3 cells. Overexpression of kinase dead Akt mutant or phosphorylation-defective CREB inhibited cyclin D1 transcriptional activity. Conclusions: The current study shows that Nexrutine-mediated targeting of Akt/CREB - induced activation of cyclin D1 prevents the progression of prostate cancer. Expression of CREB and phosphorylated CREB increased in human prostate tumors compared with normal tissue, suggesting their potential use as prognostic markers.

AB - Purpose: Development of prostate cancer prevention strategies is an important priority to overcome high incidence, morbidity, and mortality. Recently, we showed that Nexrutine, an herbal extract, inhibits prostate cancer cell proliferation through modulation of Akt and cAMP-responsive element binding protein (CREB) - mediated signaling pathways. However, it is unknown if Nexrutine can be developed as a dietary supplement for the prevention of prostate cancer. In this study, we used the transgenic adenocarcinoma of mouse prostate (TRAMP) model to examine the ability of Nexrutine to protect TRAMP mice from developing prostate cancer. Experimental Design: Eight-week-old TRAMP mice were fed with pelleted diet containing 300 and 600 mg/kg Nexrutine for 20 weeks. Efficacy of Nexrutine was evaluated by magnetic resonance imaging at 18 and 28 weeks of progression and histologic analysis of prostate tumor or tissue at the termination of the experiment. Tumor tissue was analyzed for modulation of various signaling molecules. Results: We show that Nexrutine significantly suppressed palpable tumors and progression of cancer in the TRAMP model. Expression of total and phosphorylated Akt, CREB, and cyclin D1 was significantly reduced in prostate tissue from Nexrutine intervention group compared with tumors from control animals. Nexrutine also inhibited cyclin D1 transcriptional activity in androgen-independent PC-3 cells. Overexpression of kinase dead Akt mutant or phosphorylation-defective CREB inhibited cyclin D1 transcriptional activity. Conclusions: The current study shows that Nexrutine-mediated targeting of Akt/CREB - induced activation of cyclin D1 prevents the progression of prostate cancer. Expression of CREB and phosphorylated CREB increased in human prostate tumors compared with normal tissue, suggesting their potential use as prognostic markers.

UR - http://www.scopus.com/inward/record.url?scp=34249089950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249089950&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-06-2974

DO - 10.1158/1078-0432.CCR-06-2974

M3 - Article

C2 - 17473212

AN - SCOPUS:34249089950

VL - 13

SP - 2784

EP - 2794

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -